Delivery Order SPE2DB22D2007-SPE2DB25FJ5LB
- Not listed
- The Defense Logistics Agency awarded a $6,672.74 firm fixed price delivery order to AmerisourceBergen Drug Corp for Crexont ER 87.5 mg-350 mg capsules (120 count) on September 5, 2025, with completion targeted for September 8, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $2,179.35 to AmerisourceBergen Drug Corp for CREXONT ER 52.5 MG-210 MG capsules (120-count supply) on September 12, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,272.44 to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Crexont ER 70 mg-280 mg capsules (120-count). This firm fixed price delivery order, with an ultimate completion date of September 17, 2025, represents a competitive award with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a $2,881.19 delivery order to AmerisourceBergen Drug Corp for Crexont ER 87.5 mg-350 mg capsules (120 count) on August 21, 2025, with ultimate completion by August 22, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract utilizing competitively-awarded pricing. The product will be performed at AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major...
- The Defense Logistics Agency awarded a delivery order valued at $1,192.05 to AmerisourceBergen Drug Corp for CREXONT ER 87.5 mg-350 mg capsules (120-count supply). This is a firm fixed-price delivery order with no set-aside designation, completed on September 3, 2025, and performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills this order under its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,989.09 to AmerisourceBergen Drug Corp for Crexont ER (87.5 mg-350 mg capsules, 120 count) on September 10, 2025, with an ultimate completion date of September 11, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a competitive award under DLA's existing pharmaceutical supply contract vehicle. The product will be delivered to AmerisourceBergen's corporate office location...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for CREXONT ER 70 mg–280 mg capsules (120-count packaging) with a ceiling value of $3,237.83. This firm fixed-price delivery order is non-competitive, representing one of numerous pharmaceutical supply transactions executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract will be performed at the company's...
- The Defense Logistics Agency awarded a delivery order valued at $2,501.63 to AmerisourceBergen Drug Corp for Crexont ER 70 MG-280 MG capsules (120-count supply) on August 4, 2025, with completion scheduled for August 5, 2025. This non-competitive delivery order utilizes firm fixed pricing and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical supplier to federal...
- This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The order, valued at $1,064.88, is for the supply of 120 capsules of the medication CREXONT ER 87.5 MG-350 MG. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 between Amerisourcebergen and the DLA Troop Support Medical, which provides a comprehensive...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,162.02 firm-fixed-price contract is for the delivery of CREXONT ER 52.5 MG-210 MG capsules, with a completion date of March 26, 2025. The contract is not designated as a set-aside and is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ5LBDelivery Order
The Defense Logistics Agency awarded a $1,644.39 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Crexont ER 87.5 mg-350 mg capsules (120 count) on September 26, 2025, with completion expected by September 29, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $1 billion and extending through December 2026. The prime contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceuticals and medical supplies supporting military healthcare programs worldwide across multiple therapeutic domains. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving critical federal medical procurement needs for military and veteran healthcare systems. The company's extensive contract portfolio demonstrates its capability to fulfill diverse federal medical supply requirements through open competition, with delivery orders ranging substantially in value. This particular order for Crexont reflects AmerisourceBergen's role as a strategic pharmaceutical provider supporting the Defense Health Agency and broader Department of Defense healthcare operations through its established prime vendor relationship with the DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 9/26/25 |